Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics
Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a...
HKG: 3696
Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D
Insilico Medicine (HKG: 3696) announced a strategic alliance with Bora Pharmaceuticals (TPE: 6472; OTCMKTS: BORAY)...
InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments
InSilico Medicine (HKG: 3696) announced an additional strategic collaboration with China Medical System Holdings Limited...
Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459)...
Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets
Insilico Medicine (HKG: 3696) announced a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TYO:...
Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases
Insilico Medicine (HKG: 3696) and South Korea’s SK Biopharmaceuticals announced a strategic collaboration leveraging artificial...
Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
Insilico Medicine (HKG: 3696) announced that ISM8969, jointly developed with Hygtia Therapeutics Co., Ltd., has...
Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research
Insilico Medicine (HKG: 3696) and Human Life Foundation Models (HLFM), a newly established spin-off from...
Insilico Medicine and Eterna Therapeutics Expand AI-Driven Partnership into Skin Anti-Aging and Scientific Skincare
Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced an expanded strategic...
Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis
Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced it has received...
Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection...
Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development
Insilico Medicine (HKG: 3696), a leading artificial intelligence (AI) drug discovery platform, has announced a...
Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of...
Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
Insilico Medicine (HKG: 3696), a pioneer in generative artificial intelligence (AI)-driven drug discovery, announced a...
Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M
Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial...
Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration
Insilico Medicine (HKG: 3696) and Tenacia Biotechnology, a central nervous system (CNS) specialist, announced an...
Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface
Insilico Medicine (HKG: 3696) announced the launch of PandaClaw, a transformative new feature of its...
Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases
Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,...
Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial
Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease...
Insilico Medicine Launches AI‑Powered Automated Partnering System – Transforms Biotech Business Development
Insilico Medicine (HKG: 3696), a generative AI‑driven biotech, announced the pilot launch of its Automated Partnering...